Tefferi A - Search Results

1

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Barosi G, et al. Among authors: tefferi a. Leukemia. 2008 Feb;22(2):437-8. doi: 10.1038/sj.leu.2404914. Epub 2007 Aug 30. Leukemia. 2008. PMID: 17728787 No abstract available.

2

Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms.

Tefferi A, Thibodeau SN, Solberg LA Jr. Tefferi A, et al. Blood. 1990 May 1;75(9):1770-3. Blood. 1990. PMID: 1970487 Free article.

3

Acute porphyrias: diagnosis and management.

Tefferi A, Colgan JP, Solberg LA Jr. Tefferi A, et al. Mayo Clin Proc. 1994 Oct;69(10):991-5. doi: 10.1016/s0025-6196(12)61827-8. Mayo Clin Proc. 1994. PMID: 7934198 Review.

4

Porphyrias: clinical evaluation and interpretation of laboratory tests.

Tefferi A, Solberg LA Jr, Ellefson RD. Tefferi A, et al. Mayo Clin Proc. 1994 Mar;69(3):289-90. doi: 10.1016/s0025-6196(12)61071-4. Mayo Clin Proc. 1994. PMID: 8133669 Review. No abstract available.

5

Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia.

Tefferi A, Bartholmai BJ, Witzig TE, Jenkins RB, Li CY, Hanson CA, Mesa RA, Phyliky RL. Tefferi A, et al. Cancer Genet Cytogenet. 1997 Jun;95(2):173-7. doi: 10.1016/s0165-4608(96)00249-x. Cancer Genet Cytogenet. 1997. PMID: 9169037 Review.

6

New drugs in essential thrombocythemia and polycythemia vera.

Tefferi A, Elliott MA, Solberg LA Jr, Silverstein MN. Tefferi A, et al. Blood Rev. 1997 Mar;11(1):1-7. doi: 10.1016/s0268-960x(97)90001-1. Blood Rev. 1997. PMID: 9218101 Review.

7

Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.

Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Tefferi A, et al. Semin Thromb Hemost. 1997;23(4):379-83. doi: 10.1055/s-2007-996112. Semin Thromb Hemost. 1997. PMID: 9263355 Review.

8

Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.

Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Mesa RA, et al. Among authors: tefferi a. Am J Hematol. 1999 May;61(1):10-5. doi: 10.1002/(sici)1096-8652(199905)61:1<10::aid-ajh3>3.0.co;2-i. Am J Hematol. 1999. PMID: 10331505 Free article.

9

Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia.

Yoon SY, Li CY, Mesa RA, Tefferi A. Yoon SY, et al. Among authors: tefferi a. Br J Haematol. 1999 Sep;106(3):682-8. doi: 10.1046/j.1365-2141.1999.01598.x. Br J Haematol. 1999. PMID: 10468856 Free article.

10

Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.

Michiels JJ, Barbui T, Finazzi G, Fuchtman SM, Kutti J, Rain JD, Silver RT, Tefferi A, Thiele J. Michiels JJ, et al. Among authors: tefferi a. Leuk Lymphoma. 2000 Jan;36(3-4):239-53. doi: 10.3109/10428190009148845. Leuk Lymphoma. 2000. PMID: 10674896 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,164 results

Search Page